Very risky, they are presenting data.
Aclaris Therapeutics (NASDAQ:ACRS) is up 19.9% after hours following positive results from its Phase 1 trial of ATI-450, an investigational oral MK2 inhibitor. The trial covered single ascending dose and multiple ascending dose approaches. The treatment was well tolerated at all doses and resulted in marked inhibition of TNFa, IL1ß, IL8, and IL6, the company...
But keep in mind this is Phase 1 for ACRS . Still a long road ahead. I'm not taking anything away from the company at all. Congrats on the win and I hope the momo continues but I've seen so many of these go parabolic. Needless to say, could be something to watch over the next few days "This time around, Aclaris Therapeutics Inc. has caught attention after...
Rp = Retracement Price and Fr = Fib Ratio Fibonacci Extension = Rp + Rp x (1/Fr) Fibonacci Extension = 6.57 + 6.57x(1/.382) Further Reduced = 6.57 + 17.20 = $23-$24 This assumes .382 holds and is confirmed by some intraday closing above 7.50
Looks like a 5 wave setup forming, within a descending wedge.. looking for a breakout when pattern completes
Note: This is not an investment advice but my opinion alone. Please feel free to comment. The chart of ACRS is pointing to a reversal of the downtrend. I had bought a few share a few days ago based on the chart forming what is called an bullish RSI divergence. As the price continues to drop, buyers are stepping in to pick up shares as can been seen on the RSI....
ACRS: aclaris therapts 2018-06-28 16:30:06 Detected possible positive results in drug trial
Buy at a discount ahead of the 24/12/17 PDUFA decision on A-101 in seborrheic keratosis
Two top stop points, indicate the Double Top Pattern in NASDAQ:ACRS ( Aclaris Therapeutics Inc )., supporintg the end of the bullish trend, confirmed by the Parabolic SAR indicator.